

	M34 - HALOPERIDOL (HALDOL)	
	10 years & older	MEDICATION
Version date: 2023-07-17		Effective date: 2023-09-19 (0700 hrs)

INDICATIONS
<ul style="list-style-type: none"> Acute agitation or combative behavior where the safety of the patient, health care providers and the public at large is or may be at risk

CONTRAINDICATIONS
<ul style="list-style-type: none"> Known or suspected neuroleptic malignant syndrome Known or suspected shock Known or suspected prolonged QT or prolonged QT syndrome Active seizures or suspected or known postictal delirium

ROUTE (WORK SCOPE)	INITIAL DOSE	REPEAT DOSE
INTRAMUSCULAR / INTRAVENOUS (ICP & ABOVE)	75 years & older - 2.5 to 5 mg	None
	17 up to 75 years – 5 to 10 mg	Once in 15 min if required
	10 up to 17 years – 2.5 to 5 mg	

NOTES
<ol style="list-style-type: none"> Always treat correctable underlying causes of agitation or combative behavior, such as hypoglycemia or hypoxemia, before administering haloperidol.

APPROVED BY	
	
Medical Director - Provincial EMS/PT	Associate Medical Director - Provincial EMS/PT

VERSION CHANGES (refer to X08 for change tracking)

- Revised administration table presents information for scope / route / dose more clearly